| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2141.1980.TB07147.X |
| P698 | PubMed publication ID | 7437326 |
| P50 | author | Emanuel Nečas | Q51758786 |
| P2093 | author name string | J Neuwirt | |
| P Ponka | |||
| M Cikrt | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 275-283 | |
| P577 | publication date | 1980-06-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone | |
| P478 | volume | 45 |
| Q36210096 | A lipophilic iron chelator can replace transferrin as a stimulator of cell proliferation and differentiation |
| Q56518910 | Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone |
| Q43640204 | Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron |
| Q43604355 | Dietary iron loading does not influence biliary iron excretion in rats |
| Q68070348 | Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture |
| Q34135061 | Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. |
| Q58580509 | Gastrointestinal iron excretion and reversal of iron excess in a mouse model of inherited iron excess |
| Q44277661 | Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs |
| Q34671614 | Iron chelators as therapeutic agents for the treatment of cancer. |
| Q28340584 | Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II) |
| Q44277885 | Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells |
| Q44225512 | Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes |
| Q40607123 | Oral iron-chelating therapy: the L1 experience |
| Q71869287 | Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone |
| Q44264337 | Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties |
| Q42195202 | Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry |
| Q74525328 | Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease |
| Q38648357 | The development of iron chelating drugs |
| Q64973488 | The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. |
| Q67885483 | Toxicological Study of Pyridoxal Isonicotinoyl Hydrazone: Acute and Subchronic Toxicity |
Search more.